FIELD: biotechnology.
SUBSTANCE: invention is a solubilized human apyrase containing modifications: N-terminal deletion, C-terminal deletion and modification of the central region, where the length of the N-terminal deletion is from 30 to 50 amino acids, the length of the C-terminal deletion is from 20 to 40 amino acids, and the modification of the central region includes a deletion of 10 to 15 consecutive amino acids, where the deletion is a deletion of amino acids 193 to 204 relative to the wild-type CD39 sequence according to SEQ ID NO: 1 and where the modification of the central region includes a point mutation involving one, two, three, four or five point mutations relative to the wild-type CD39 sequence according to SEQ ID NO: 1 selected from the group consisting of K71E, N73Q, V95A, G102D, Y104S, T106S, R113M, L149M, V151A, E173D, T229A, L254M, K258R, W263R, E276D, N292Q, R304G, I319T, N327Q, F365SN N371Q, K405N, Y412F, L424Q, H436D, I437N, F439S, G441D, N457Q, P463S and S469R. The invention also relates to a pharmaceutical composition for the treatment of tissue damage, containing a therapeutically effective dose of apyrase and one or more pharmaceutically acceptable carriers.
EFFECT: invention improves the efficiency of tissue damage treatment.
16 cl, 12 dwg, 35 tbl, 16 ex
Title | Year | Author | Number |
---|---|---|---|
POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
MULTIVALENT AND MULTI-SPECIFIC 41BB-BINDING FUSED PROTEINS | 2017 |
|
RU2789648C2 |
PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
CHIMERIC ANTIGEN RECEPTORS TARGETING CD70 | 2019 |
|
RU2801824C2 |
CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
ANTIBODIES DIRECTED AGAINST Fc-RECEPTOR-LIKE PROTEIN 5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2774158C2 |
Authors
Dates
2023-03-15—Published
2019-07-17—Filed